Vernalis PLC Signs Drug-Discovery Deal With Genentech

Published: Jan 04, 2012

U.K. drug developer Vernalis PLC said Wednesday it has signed a drug discovery collaboration with Roche Holding AG's unit Genentech. The company didn't give any financial details of the collaboration which will use Vernalis' drug discovery platform against an undisclosed target. Vernalis, which focuses on diseases of the central nervous system and cancer, has previously said it will focus on partnerships to fund its research activities.

Back to news